Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on Thestage of the disease

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 1947-1953

  Adhami, Vaqar Mustafa ^a   Siddiqui, Imtiaz Ahmad ^a   Sarfaraz, Sami ^a   Khwaja, Sabih Islam ^a   Hafeez, Bilal Bin ^a   Ahmad, Nihal ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN TEA EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL DERIVATIVE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER STAGING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME INHIBITION; LIFE EXPECTANCY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

ADENOCARCINOMA; ANIMALS; ANTICARCINOGENIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; FLAVONOIDS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; NEOPLASM STAGING; PHENOLS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TEA;

EID: 63549136229     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2332     Document Type: Article

References (38)

1. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007;16:2193-203.
2. Adhami VM, Mukhtar H. Anti-oxidantsfrom green tea and pomegranate for chemoprevention of prostate cancer.MolBiotechnol 2007;37:52-7.
3. Boyle P, Severi G. Epidemiology of prostate cancer chemoprevention. Eur Urol 1999;35:370-6.
4. Hsing AW,TsaoL, Devesa SS. International trendsand patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
5. PetoJ. Cancer epidemiology in the last century and the next decade. Nature 2001;411:390-5.
6. AngwafoFF. Migration and prostate cancer: an international perspective. J Natl Med Assoc 1998;90: S720-3.
7. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108: 130-5.
8. Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci 2007;81:519 -33.
9. Siddiqui IA, Afaq F, Adhami VM, Mukhtar H. Prevention of prostate cancer through custom tailoring of chemopreventive regimen. Chem Biol Interact 2008; 171:122-32.
10. Adhami VM, Afaq F, Mukhtar H. Insulin-like growth factor-I axis as a pathway for cancer chemopreven- tion. Clin Cancer Res 2006;12:5611-4.
11. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-5.
12. SiddiquiIA,AfaqF,AdhamiVM,AhmadN, Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004;6:571 -82.
13. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H.Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5.
14. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphe- nols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004;64:8715-22.
15. Siddiqui IA, ShuklaY, Adhami VM, et al. Suppression of NFκB and its regulated gene products by oral administration of green tea polyphenolsin an autochthonous mouse prostate cancer model. Pharm Res 2008; 25:2135-42.
16. Choan E, Segal R, Jonker D, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005;23: 108-13.
17. JatoiA,Ellison N,Burch PA, et al. Aphase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;7:1442-6.
18. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G,Peracchia G,Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. CancerRes2006;66:1234-40.
19. Brausi M, Rizzi F, Bettuzzi S. chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54: 472 -3.
20. Greenberg NM, DeMayoF, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A1995;92:3439 -43.
21. Greenberg NM., DeMayoFJ, Sheppard PC, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heter- ologous gene specifically to the prostatein transgenic mice. Mol Endocrinol 1994;8:230-9.
22. McCarthy S, Caporali A, Enkemann S, et al. Green tea catechins suppress the DNA synthesis marker MCM7 in theTRAMP model of prostate cancer. Mol Oncol 2007;1:196-204.
23. Harper CE,Patel BB,WangJ,Eltoum IA,Lamartiniere CA. Epigallocatechin-3- gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate2007;67:1576 -89.
24. Sartor L, Pezzato E, Dona M, etal. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murineTRAMP model. Int J Cancer 2004; 112:823-9.
25. Caporali A, Davalli P, Astancolle S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25:2217 -24.
26. Scaltriti M, Belloni L, Caporali A, et al. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis 2006;27:1047 -53.
27. Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2008. CACancerJ Clin 2008;58:71 -96.
28. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006;12:3661 -97.
29. Surh YJ. Cancer chemoprevention with dietaryphytochemicals. Nat Rev Cancer 2003;3:768-80.
30. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099 -106.
31. Kulik G, Klippel A,Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phos-phatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17:1595-606.
32. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003;100:7841 -6.
33. LambertJD, Sang S,Yang CS. Possible controversy over dietary polyphenols: benefits vs risks. Chem Res Toxicol2007;20:583-5.
34. Foster BA, Kaplan PJ, Greenberg NM. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev1998-1999;17: 317 -24.
35. Kaplan PJ,Mohan S,Cohen P,Foster BA,Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate(TRAMP) model. Cancer Res1999; 59:2203-9.
36. Koistinen H, Paju A, Koistinen R, et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 2002;50:112 -8.
37. Neuhouser ML, Schenk J, Song YJ, et al. Insulinlike growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 2008;68:1477-86.
38. Finne P, Auvinen A, Koistinen H, et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000;85: 2744-7.